Top 10 cystic fibrosis stories of 2022

Healio Pulmonology has compiled the top news on cystic fibrosis posted in 2022.

Our most-read stories of the year include data on an inhalation therapy, the FDA’s approval of lumacaftor and ivacaftor (Orkambi, Vertex Pharmaceuticals) for children, vitamin C impacting alpha-tocopherol concentrations, a higher BMI leading to favorable outcomes and the benefits and limitations of newborn screening.

Here are Healio’s top 10 most-read stories on cystic fibrosis from 2022.

Inhalation therapy containing manuka honey, amikacin shows promise for respiratory infections

Combining manuka honey and the antibiotic amikacin in a lab-based nebulization formulation was effective for inhibiting Mycobacterium abscessus and drug-resistant clinical isolates in patients with cystic fibrosis or bronchiectasis. Read more.

FDA expands approval of Orkambi for young children with cystic fibrosis

The FDA expanded the approval of lumacaftor and ivacaftor to include the treatment of children with cystic fibrosis aged 1 year to younger than 2 years, according to a manufacturer-issued press release. Read more.

Vitamin C augments concentration of alpha-tocopherol in cystic fibrosis

Among adults with cystic fibrosis, vitamin C decreased the plasma disappearance rate of alpha-tocopherol, thereby augmenting its concentrations, according to a study published in Nutrients. Read more.

Higher BMI associated with favorable clinical outcomes in patients with cystic fibrosis

In a systematic review and meta-analysis, researchers found higher BMI was associated with favorable clinical outcomes in patients with cystic fibrosis, urging reconsideration of the currently recommended target BMI. Read more.

Black, Asian infants with cystic fibrosis more likely to be missed on newborn screening

Black and Asian infants with cystic fibrosis had the lowest rates of detection during newborn screening, whereas white infants had the highest rates, according to a study published in Pediatric Pulmonology. Read more.

Wearable technology shows promise in assessing physical activity, cough in cystic fibrosis

Patients receiving treatment for cystic fibrosis wore actigraphy sensors and cough monitoring systems for the majority of a 12-week period, according to a poster presented at the North American Cystic Fibrosis Conference. Read more.

US cystic fibrosis newborn screening programs led to improved nutritional, pulmonary outcomes

In the U.S., newborn screening programs for cystic fibrosis were associated with improved nutritional status up to middle childhood, rapid increases in lung function and delayed chronic Pseudomonas aeruginosa infection, researchers reported. Read more.

Appetite stimulants show positive weight gain in children with cystic fibrosis

Children with cystic fibrosis gained weight within the first 3 months of appetite stimulant therapy, according to a poster presented at the North American Cystic Fibrosis Conference. Read more.

Oscillatory positive expiratory pressure device may preserve lung function in children

Use of an oscillatory positive expiratory pressure device alone or with additional airway clearance improved lung function among children with cystic fibrosis, according to data presented at the North American Cystic Fibrosis Conference. Read more.

High-dose vitamin D therapy successful for patients with cystic fibrosis

Vitamin D levels in patients with a deficiency and cystic fibrosis increased with a single high dose, or stoss therapy, according to a poster presented at the North American Cystic Fibrosis Conference. Read more.